The efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory patients - A prospective, randomised, double-blind, placebo-controlled study

Basit Öğe Kaydı
dc.contributor.authorDursun, M
dc.contributor.authorCaliskan, M
dc.contributor.authorCanoruc, F
dc.contributor.authorAluclu, U
dc.contributor.authorCanoruc, N
dc.contributor.authorTuzcu, A
dc.contributor.authorYilmaz, S
dc.date.accessioned2024-04-24T17:44:43Z
dc.date.available2024-04-24T17:44:43Z
dc.date.issued2003
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives: Hepatic encephalopathy (HE) is a neuropsychiatric syndrome associated with fulminant hepatic failure and chronic liver disease. Its pathogenesis is unclear. One of the factors implicated is enhanced GABA-ergic tone, which is probably related to increased concentrations of cerebral benzodiazepine (BNZ). In the present study, we tested flumazenil, a cerebral BNZ antagonist, in cirrhosis patients with hepatic encephalopathy. Methods: Out of 47 patients, 7 were excluded prior to randomization for various reasons. Twenty patients were included in the flumazenil group and 20 in the placebo group in a prospective, randomized, double-blind, placebo-controlled study. Patients were given. flumazenil (1 mg/h, continuous IV infusion) or an equal volume of saline solution for 5 hours. Before and after treatment, portosystemic encephalopathy (PSE) stage and number connection test (NCT) scores were checked every half hour for 5 hours. EEG was recorded 15 minutes before and I hour after treatment. Results: While significant improvements were determined in PSE stage and NCT score in the flumazenil group, there were no such improvements in the placebo group. There was no statistically significant difference between pre- and post-treatment EEGs in either group. Conclusion: It was concluded that continuous IV infusion of flumazenil had beneficial and safe effects in the treatment of hepatic encephalopathy patients.en_US
dc.identifier.endpage123en_US
dc.identifier.issn1424-7860
dc.identifier.issn1424-3997
dc.identifier.issue7-8en_US
dc.identifier.pmid12644958
dc.identifier.startpage118en_US
dc.identifier.urihttps://hdl.handle.net/11468/22251
dc.identifier.volume133en_US
dc.identifier.wosWOS:000182365500003
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherE M H Swiss Medical Publishers Ltden_US
dc.relation.ispartofSwiss Medical Weekly
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatic Encephalopathyen_US
dc.subjectFlumazenilen_US
dc.titleThe efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory patients - A prospective, randomised, double-blind, placebo-controlled studyen_US
dc.titleThe efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory patients - A prospective, randomised, double-blind, placebo-controlled study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu